FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2793779271> ?p ?o ?g. }

• W2793779271 endingPage "10548" @default.
• W2793779271 startingPage "10536" @default.
• W2793779271 abstract "// Sinead A. Noonan 1, * , Maria E. Morrissey 2, * , Petra Martin 1 , Monika Biniecka 3 , Shane Ó’Meachair 4 , Aoife Maguire 5 , Miriam Tosetto 1 , Blathnaid Nolan 1 , John Hyland 1 , Kieran Sheahan 1 , Diarmuid O’Donoghue 1 , Hugh Mulcahy 1 , David Fennelly 1 and Jacintha O’Sullivan 2 1 Centre for Colorectal Disease, St. Vincent’s University Hospital, University College Dublin, Dublin, Ireland 2 Trinity Translational Medicine Institute (TTMI), Department of Surgery, Trinity College Dublin, St James’s Hospital, Dublin, Ireland 3 Education and Research Centre, St. Vincent’s University Hospital, University College Dublin, Dublin, Ireland 4 Centre for Health Decision Science (CHeDS), School of Computer Science and Statistics, Trinity College Dublin, Dublin, Ireland 5 Department of Histopathology, St. James’s Hospital, Dublin, Ireland * These authors have contributed equally to this work Correspondence to: Jacintha O’Sullivan, email: osullij4@tcd.ie Keywords: bevacizumab; predictive biomarkers; metastatic colorectal cancer; vasculature; inflammation Abbreviations: mCRC: Metastatic colorectal cancer; VEGF: vascular endothelial growth factor; FFPE: formalin-fixed, paraffin-embedded; TMA: tissue microarrays; OS: overall survival Received: September 08, 2017      Accepted: January 02, 2018      Published: January 19, 2018 ABSTRACT Despite treatment of patients with metastatic colorectal cancer (mCRC) with bevacizumab plus chemotherapy, response rates are modest and there are no biomarkers available that will predict response. The aim of this study was to assess if markers associated with three interconnected cancer-associated biological processes, specifically angiogenesis, inflammation and oxidative damage, could stratify the survival outcome of this cohort. Levels of angiogenesis, inflammation and oxidative damage markers were assessed in pre-bevacizumab resected tumour and serum samples of mCRC patients by dual immunofluorescence, immunohistochemistry and ELISA. This study identified that specific markers of angiogenesis, inflammation and oxidative damage stratify survival of patients on this anti-angiogenic treatment. Biomarkers of immature tumour vasculature (% IMM, p=0.026, n=80), high levels of oxidative damage in the tumour epithelium (intensity of 8-oxo-dG in nuclear and cytoplasmic compartments, p=0.042 and 0.038 respectively, n=75) and lower systemic pro-inflammatory cytokines (IL6 and IL8, p=0.053 and 0.049 respectively, n=61) significantly stratify with median overall survival (OS). In summary, screening for a panel of biomarkers for high levels of immature tumour vasculature, high levels of oxidative DNA damage and low levels of systemic pro-inflammatory cytokines may be beneficial in predicting enhanced survival outcome following bevacizumab treatment for mCRC." @default.
• W2793779271 created "2018-03-29" @default.
• W2793779271 creator A5002013891 @default.
• W2793779271 creator A5011616471 @default.
• W2793779271 creator A5013624985 @default.
• W2793779271 creator A5020691740 @default.
• W2793779271 creator A5023152070 @default.
• W2793779271 creator A5032626903 @default.
• W2793779271 creator A5036984314 @default.
• W2793779271 creator A5040600350 @default.
• W2793779271 creator A5050821384 @default.
• W2793779271 creator A5060116963 @default.
• W2793779271 creator A5070588896 @default.
• W2793779271 creator A5074441283 @default.
• W2793779271 creator A5080089607 @default.
• W2793779271 creator A5087034199 @default.
• W2793779271 date "2018-01-19" @default.
• W2793779271 modified "2023-10-12" @default.
• W2793779271 title "Tumour vasculature immaturity, oxidative damage and systemic inflammation stratify survival of colorectal cancer patients on bevacizumab treatment" @default.
• W2793779271 cites W1539571840 @default.
• W2793779271 cites W1553048017 @default.
• W2793779271 cites W1804113097 @default.
• W2793779271 cites W1872839506 @default.
• W2793779271 cites W1878663564 @default.
• W2793779271 cites W1898161046 @default.
• W2793779271 cites W1953357409 @default.
• W2793779271 cites W1963832292 @default.
• W2793779271 cites W1965037168 @default.
• W2793779271 cites W1966527204 @default.
• W2793779271 cites W1973232671 @default.
• W2793779271 cites W1985712533 @default.
• W2793779271 cites W1988307856 @default.
• W2793779271 cites W1991392376 @default.
• W2793779271 cites W1996114369 @default.
• W2793779271 cites W2000447200 @default.
• W2793779271 cites W2003447301 @default.
• W2793779271 cites W2010194757 @default.
• W2793779271 cites W2011084692 @default.
• W2793779271 cites W2012852444 @default.
• W2793779271 cites W2013282590 @default.
• W2793779271 cites W2014628434 @default.
• W2793779271 cites W2014986361 @default.
• W2793779271 cites W2020383780 @default.
• W2793779271 cites W2025097579 @default.
• W2793779271 cites W2030620101 @default.
• W2793779271 cites W2041486092 @default.
• W2793779271 cites W2042765071 @default.
• W2793779271 cites W2042884540 @default.
• W2793779271 cites W2047717400 @default.
• W2793779271 cites W2066973685 @default.
• W2793779271 cites W2073045469 @default.
• W2793779271 cites W2076204388 @default.
• W2793779271 cites W2079265161 @default.
• W2793779271 cites W2088571368 @default.
• W2793779271 cites W2096396175 @default.
• W2793779271 cites W2096720100 @default.
• W2793779271 cites W2112313646 @default.
• W2793779271 cites W2112940666 @default.
• W2793779271 cites W2116974118 @default.
• W2793779271 cites W2117692326 @default.
• W2793779271 cites W2122298066 @default.
• W2793779271 cites W2124635565 @default.
• W2793779271 cites W2133421024 @default.
• W2793779271 cites W2147297736 @default.
• W2793779271 cites W2149199519 @default.
• W2793779271 cites W2157019123 @default.
• W2793779271 cites W2157546585 @default.
• W2793779271 cites W2159789252 @default.
• W2793779271 cites W2161279557 @default.
• W2793779271 cites W2164664027 @default.
• W2793779271 cites W2164882879 @default.
• W2793779271 cites W2186364980 @default.
• W2793779271 cites W2252567929 @default.
• W2793779271 cites W2276692235 @default.
• W2793779271 cites W2297843096 @default.
• W2793779271 cites W2514315625 @default.
• W2793779271 cites W2516125803 @default.
• W2793779271 cites W2569551489 @default.
• W2793779271 cites W2582448936 @default.
• W2793779271 cites W2594944671 @default.
• W2793779271 cites W2606328160 @default.
• W2793779271 cites W2607395935 @default.
• W2793779271 cites W2610204288 @default.
• W2793779271 cites W2614442853 @default.
• W2793779271 cites W2617441524 @default.
• W2793779271 cites W2620438284 @default.
• W2793779271 cites W303744132 @default.
• W2793779271 cites W4211199921 @default.
• W2793779271 cites W4211213217 @default.
• W2793779271 cites W4237928317 @default.
• W2793779271 doi "https://doi.org/10.18632/oncotarget.24276" @default.
• W2793779271 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5828217" @default.
• W2793779271 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29535825" @default.
• W2793779271 hasPublicationYear "2018" @default.
• W2793779271 type Work @default.
• W2793779271 sameAs 2793779271 @default.
• W2793779271 citedByCount "8" @default.
• W2793779271 countsByYear W27937792712018 @default.

• next